Expression of Axl and Its Prognostic Significance in Human Breast Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Mar 31

PMID 28356938

Citations 11

Authors

Gaoyuan Jin

Zhenzhen Wang

Jianguang Wang

Like Zhang

Yanbin Chen

Pengfei Yuan

Dechun Liu

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common malignant cancer and second leading cause of cancer-related death among women, and its prevalence continues to increase. Axl overexpression has been identified in the many types of human cancer, and it has been demonstrated to participate in signaling pathways related to carcinogenesis and cancer development. In the present study, Axl expression was examined by performing immunohistochemical staining in 60 breast cancer tumors and 40 benign breast lesions (25 mammary dysplasia and 15 breast fibroadenoma). In total, 34 (56.67%) cancer tissues and 13 (32.5%) benign breast lesions were classified as exhibiting high levels of Axl expression, indicating a significant association between malignancy and high Axl expression. High Axl expression was also associated with estrogen receptor (ER) positivity (P=0.028), progesterone receptor (PR) positivity (P=0.007), and poor tumor differentiation (P=0.033). No significant associations were observed between Axl expression and age, tumor size, lymph node metastasis, tumor node metastasis staging, human epidermal growth factor receptor 2 and Ki67 antigen. The Kaplan-Meier survival analysis and Cox proportional hazard model both demonstrated that there was no statistical difference between Axl expression and breast cancer prognosis. However, it remains unclear whether the expression of Axl is correlated with the prognosis of luminal type breast cancer patients.

Citing Articles

Expression of Axl Receptor Tyrosine Kinase and Its Association With Ki-67 Proliferation Marker, BCL-2 Anti-apoptotic Protein, Hormone Receptor Status, and HER2/Neu Status in Breast Cancer Among Women From Duhok, Iraq.

Mohammed S, Al Mahmoodi H, Yalda M Cureus. 2024; 16(9):e70204.

PMID: 39463509 PMC: 11510083. DOI: 10.7759/cureus.70204.

First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.

Bardol T, Eslami-S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, Bobrie A Cancer Med. 2023; 13(1):e6843.

PMID: 38132919 PMC: 10807582. DOI: 10.1002/cam4.6843.

A FBXO7/EYA2-SCF axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.

Shen J, Qiu Z, Wu Q, Zhang G, Harris R, Sun D Mol Cell. 2022; 82(6):1123-1139.e8.

PMID: 35182481 PMC: 8934274. DOI: 10.1016/j.molcel.2022.01.022.

SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.

Synn C, Kim S, Lee H, Kim M, Kim J, Lee J Clin Transl Immunology. 2022; 11(1):e1364.

PMID: 35003748 PMC: 8716998. DOI: 10.1002/cti2.1364.

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.

Fatima M, Kakar S, Adnan F, Khan K, Mian A, Khan D BMC Cancer. 2021; 21(1):713.

PMID: 34140003 PMC: 8210361. DOI: 10.1186/s12885-021-08450-y.

References

Wu C, Li A, Chi C, Lai C, Huang C, Lo S . Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 2002; 22(2B):1071-8. View

Ahmed L, Nalwoga H, Arnes J, Wabinga H, Micklem D, Akslen L . Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women. APMIS. 2015; 123(8):688-96. DOI: 10.1111/apm.12403. View

Li Y, Jia L, Ren D, Liu C, Gong Y, Wang N . Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma. IUBMB Life. 2014; 66(7):507-18. DOI: 10.1002/iub.1285. View

Tai K, Shieh Y, Lee C, Shiah S, Wu C . Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene. 2008; 27(29):4044-55. DOI: 10.1038/onc.2008.57. View

Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X . Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014; 2(7):61. PMC: 4202458. DOI: 10.3978/j.issn.2305-5839.2014.04.05. View

Sayan A, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K . Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene. 2011; 31(12):1493-503. DOI: 10.1038/onc.2011.336. View

Berclaz G, Altermatt H, Rohrbach V, Kieffer I, Dreher E, Andres A . Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol. 2001; 12(6):819-24. DOI: 10.1023/a:1011126330233. View

Craven R, Xu L, Weiner T, Fridell Y, Dent G, Srivastava S . Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995; 60(6):791-7. DOI: 10.1002/ijc.2910600611. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

10.

Holland S, Powell M, Franci C, Chan E, Friera A, Atchison R . Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 2005; 65(20):9294-303. DOI: 10.1158/0008-5472.CAN-05-0993. View

11.

Al-Muhtaseb S . Serum and saliva protein levels in females with breast cancer. Oncol Lett. 2014; 8(6):2752-2756. PMC: 4214488. DOI: 10.3892/ol.2014.2535. View

12.

Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I . Prognostic markers in triple-negative breast cancer. Cancer. 2006; 109(1):25-32. DOI: 10.1002/cncr.22381. View

13.

Haffty B, Yang Q, Reiss M, Kearney T, Higgins S, Weidhaas J . Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24(36):5652-7. DOI: 10.1200/JCO.2006.06.5664. View

14.

OBryan J, Frye R, Cogswell P, Neubauer A, Kitch B, Prokop C . axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991; 11(10):5016-31. PMC: 361494. DOI: 10.1128/mcb.11.10.5016-5031.1991. View

15.

Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J . Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol. 2012; 20 Suppl 3:S467-76. PMC: 3853411. DOI: 10.1245/s10434-012-2795-3. View

16.

Carlson R, Moench S, Hammond M, Perez E, Burstein H, Allred D . HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006; 4 Suppl 3:S1-22. View

17.

Neve R, Chin K, Fridlyand J, Yeh J, Baehner F, Fevr T . A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-27. PMC: 2730521. DOI: 10.1016/j.ccr.2006.10.008. View

18.

Lim J, Thiery J . Epithelial-mesenchymal transitions: insights from development. Development. 2012; 139(19):3471-86. DOI: 10.1242/dev.071209. View

19.

Shiozawa Y, Pedersen E, Patel L, Ziegler A, Havens A, Jung Y . GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010; 12(2):116-27. PMC: 2814350. DOI: 10.1593/neo.91384. View

20.

Song X, Wang H, Logsdon C, Rashid A, Fleming J, Abbruzzese J . Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2010; 117(4):734-43. PMC: 4403266. DOI: 10.1002/cncr.25483. View